Publication:
Potential of recombinant 2-Cys peroxiredoxin protein as a vaccine for Fasciola gigantica infection

dc.contributor.authorKant Sangpairojen_US
dc.contributor.authorSomjai Apisawetakanen_US
dc.contributor.authorNarin Changklungmoaen_US
dc.contributor.authorPornanan Kueakhaien_US
dc.contributor.authorPannigan Chaichanasaken_US
dc.contributor.authorPrasert Sobhonen_US
dc.contributor.authorKulathida Chaithirayanonen_US
dc.contributor.otherFaculty of Medicine, Thammasat Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherMahanakorn University of Technologyen_US
dc.contributor.otherBurapha Universityen_US
dc.contributor.otherSrinakharinwirot Universityen_US
dc.date.accessioned2019-08-23T11:16:49Z
dc.date.available2019-08-23T11:16:49Z
dc.date.issued2018-11-01en_US
dc.description.abstract© 2018 Helminth 2-cys peroxiredoxin (Prx) is a major antioxidant enzyme that protects parasites against hydrogen peroxide-generating oxidative stress from the hosts’ immune responses. This enzyme has been found in all stages of the tropical liver fluke, Fasciola gigantica. To investigate the potential of the recombinant F. gigantica Prx-2 (rFgPrx-2) as a vaccine candidate, vaccine trials in mice were carried out. In this study, the ICR mice were immunized with rFgPrx-2 combined with Freund's adjuvant and infected with F. gigantica metacercariae. The vaccine efficacy was estimated by quantitate fluke recovery, antibody levels and liver function. The protection by rFgPrx-2 against F. gigantica infection was achieved at 43–46% compared with adjuvant-infected and non-immunized-infected control groups, respectively. The vaccine elicited both Th1 and Th2 humoral immune responses with predominance of Th2 as indicated by the higher level of IgG1 in sera of immunized mice. However, the levels of liver damage markers, serum glutamate oxalic transaminase (SGOT) and serum glutamic pyruvate transaminase (SGPT) in rFgPrx-2 immunized group did not show significant difference in comparison with the controls. This study suggested that rFgPrx-2 may have a potential as a vaccine against tropical fasciolosis.en_US
dc.identifier.citationExperimental Parasitology. Vol.194, (2018), 16-23en_US
dc.identifier.doi10.1016/j.exppara.2018.09.005en_US
dc.identifier.issn10902449en_US
dc.identifier.issn00144894en_US
dc.identifier.other2-s2.0-85054808400en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/45948
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85054808400&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titlePotential of recombinant 2-Cys peroxiredoxin protein as a vaccine for Fasciola gigantica infectionen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85054808400&origin=inwarden_US

Files

Collections